Girard Sharp LLP is investigating potential claims on behalf of PACS Group, Inc. (NYSE: PACS) shareholders.
If you are a current or former PACS Group, Inc. shareholder, fill out our form or call (866) 981-4800 for a free consultation.
PACS Group Under Investigation After 27% Stock Drop
PACS Group, Inc. is a $6.7 billion holding company that invests in various healthcare platforms, including senior living communities, post-acute care facilities, and ancillary services. On November 2, 2024, an article was published by Hindenburg Research, alleging PACS managed stock prices by “scamming taxpayer-funded health care programs.” The cost of PACS Group, Inc.’s stock has dropped 27% following this news.
Are you a current or former PACS Group, Inc. shareholder? Please call (866) 981-4800 for a free consultation today.
Our Commitment to Excellence
Girard Sharp represents investors, consumers, and institutions in class actions and other complex litigation nationwide. We serve on the Plaintiffs’ executive committee in the recent spoofing litigation against JPMorgan Chase that settled for $60 million, a favorable resolution that the district court preliminarily approved in December 2021. We recently obtained a $36.5 million securities settlement against Maxar Technologies, a space imagery company, after its share price collapsed following its acquisition of DigitalGlobe. Our attorneys have obtained multimillion-dollar recoveries for victims of unfair and deceptive practices in antitrust, financial fraud, and consumer protection matters against some of the country’s largest corporations, including Raymond James, John Hancock, and Sears. Girard Sharp has earned top-tier rankings from U.S. News and World Report for Securities and Class Action Litigation and has been repeatedly selected as an Elite Trial Lawyers finalist by the National Law Journal.
